Belvedere Trading
DNA icon

Belvedere Trading’s Ginkgo Bioworks DNA Stock Holding History

Belvedere Trading’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,400
Closed -$7.01K – 806
2025
Q4 		$7.01K Hold
33,400
– – ﹤0.01% 777
2025
Q3 		$11.4K Hold
33,400
– – ﹤0.01% 792
2025
Q2 		$9.02K Hold
33,400
– – ﹤0.01% 725
2025
Q1 		$5.34K Sell
33,400
-1,800
-5% -$18.3K ﹤0.01% 616
2024
Q4 		$25.7K Buy
+35,200
New +$302K ﹤0.01% 668
2023
Q1 		– Sell
-418
Closed -$28.2K – 1055
2022
Q4 		$28.2K Buy
+418
New +$38.4K ﹤0.01% 771
2022
Q2 		– Sell
-920
Closed -$141K – 412
2022
Q1 		$141K Buy
920
+45
+5% +$8.76K ﹤0.01% 280
2021
Q4 		$185K Buy
+875
New +$416K 0.01% 218

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belvedere Trading's DNA Position: Q1 2026 in Review

Belvedere Trading sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 177 shares — an estimated $1.47K sold.

Belvedere Trading first reported a position in DNA in Q3 2021 and held it in 3 quarters. The position peaked at $343K in Q3 2021. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Belvedere Trading reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Belvedere Trading sold 177 Ginkgo Bioworks shares in Q1 2026, an estimated $1.47K.
  • Belvedere Trading first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 3 quarters.
  • Belvedere Trading's Ginkgo Bioworks position peaked at $343K in Q3 2021.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.